BioSpace News Archive

Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced that the first patient has been dosed with AB248 in a Phase 1 first-in-human study, AB248-101.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close.

Xenetic Biosciences, Inc. today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,001,543 titled, Method to Improve Safety and Efficacy of Anti-Cancer Therapy.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.

Neuronetics, Inc. announced a new peer-reviewed publication in the Journal of Clinical Psychiatry, presenting real-world evidence of the efficacy of NeuroStar Advanced Therapy for adult patients who suffer concurrently from anxiety symptoms and major depressive disorder, also known as anxious depression.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference, taking place on Wednesday, January 18, 2023, at 11:00 a.m. EST.

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, announced the following promotions within the organization:

Ultomiris (ravulizumab) has been approved in Canada for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.1 [PM, p.4A]

Willow Biosciences Inc. announced today a follow-on engagement with Sandhill One, LLC (www.sandhillone.com) (“Sandhill”) for the next phase in optimizing a proprietary enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (“API”) used in nutraceutical and pharmaceutical products.

GermStopSQ has been issued a Notice of Compliance by Health Canada and granted a Drug Identification Number, making Good Theorem the first to launch a residual* disinfectant that keeps killing 99.999% of bacteria and 99.9% of Human Coronavirus 229E for 24 hours, making it the first of its kind on the market.